This clinical research study is following changes in bone mineral density over time when Myfembree is used for up to 4 years and for 1 year after treatment is stopped. Currently, this medication is approved by the FDA for up to 2 years of use for the management of premenopausal women with heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain associated with endometriosis.

The eCoin device is an FDA approved tibial nerve stimulator used for the treatment of urgeny urinary incontinence. The purpose of this study is to evaluate the effectiveness of sensory and subsensory amplitudes with eCoin tibial nerve stimulation in urgency urinary incontinence episodes and quality of life.

This clinical research study is evaluating the effectiveness of an investigational medication in postmenopausal females, 40-75 years of age, with symptoms of vaginal atrophy, including pain with sexual activity.

The purpose of this study is to learn if filling the uterus with a soft gel-like material (Juveena Hydrogel) at the end of your gynecological surgical procedure can safely and effectively reduce the development of intrauterine adhesions (fibrous scar tissue).

The Intibia is a single-use, programmable implantable tibial nerve stimulator. The purpose of this study is to demonstrate the safety and effectiveness of the INTIBIA system for the treatment of urge urinary incontinence.

The ELARIS EM-COC study is evaluating the safety and effectiveness of an oral investigational medication when taken together with a combined oral contraceptive that contains estrogen and progesterone, in premenopausal women that are experiencing endometriosis pain.